BofA analyst Jason Gerberry raised the firm’s price target on Axsome Therapeutics (AXSM) to $118 from $106 and keeps a Buy rating on the shares after a 3Q update that included a revenue beat and “encouraging” pipeline updates. Updates on the timing of two ongoing Phase 3 Auvelity ADA trials clarifies the catalyst event path with both studies set to readout simultaneously in Q4, says the firm, which believes Axsome only needs to hit one of two ADA trials to “remove any overhang regarding regulatory prospects for the important label expansion.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AXSM:
- Axsome Therapeutics price target raised to $116 from $112 at Baird
- Axsome Therapeutics’ Strong Q3 Growth Amidst Strategic Expansions
- Axsome Therapeutics reports Q3 EPS ($1.34), consensus ($1.41)
- Axsome Therapeutics expects cash to fund operations into cash flow positivity
- AXSM Earnings this Week: How Will it Perform?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
